血塞通注射液降低COPD患者肺动脉高压的作用及其机制

目的:观察血塞通注射液降低COPD患者肺动脉高压的临床作用并探讨其可能机制。方法:将22例确诊慢性阻塞性肺疾病患者随机分为常规治疗组和血塞通治疗组,随机抽取11例无肺疾患正常人作为对照组。常规治疗组予支气管扩张剂、抗生素及吸入糖皮质激素,血塞通治疗组在常规治疗基础上加用血塞通针,正常对照组不予任何治疗措施,2周后比较3组肺功能、肺动脉压及血气分析,ELISA法检测血浆磷酸化Erk1/2、磷酸化P38MAPK蛋白表达情况,评价血塞通注射液对慢性阻塞性肺疾病肺动脉高压的影响及与MAPKs信号通路的关系。结果:(1)常规组和血塞通组治疗后肺动脉压、肺功能及血气分析各项指标均较治疗前明显改善,且血塞通组优于常规组(均P0.05);(2)ELISA结果:血塞通组综合治疗后血浆p-ERK、p-P38表达降低(均P0.01),常规组无明显差异(P0.05),两组比较有统计学差异(均P0.05)。结论:血塞通注射液可能通过抑制P38MAPK、ERK1/2通路,有效地降低COPD患者肺动脉压,改善肺功能。

Effect and Mechanism of Xueshuantong Injection on Alleviating Pulmonary Arterial Hypertension in COPD Patients

Objective:To observe the effect of Xuesaitong injection on pulmonary hypertension in chronic obstructive pulmonary disease(COPD)patients and investigate its possible mechanism.Methods:22 cases of patients with COPD were randomly divided into conventional treatment group(group C)and Xuesaitong treatment group(group T),11 patients were randomly selected from healthy subjects without lung disease served as normal control group(group N).group C was given standardizing normal drugs,and group T was added with Xueshuantong injection on the basis treatment above,group N was given no treatment.After 2 weeks,lung function,pulmonary arterial pressure and blood gas analysis were compared,and the protein expressions of phosphorylated Erk1/2 and phosphorylated P38MAPK in plasma were tested.Results:(1)After treatment,in group T and group C pulmonary artery pressure,pulmonary function and blood gas analysis were obviously improved(P<0.05),and group T was better than group C(P<0.05).(2)ELISA results:in group T the expressions of p-ERK and p-P38 were decreased(P<0.01),group C had no significant difference(P>0.05),and there was a significant difference between the two groups(P<0.05).Conclusion:Combination with Xuesaitong injection can effectively reduce pulmonary artery pressure,improve lung function and blood gas analysis.(3)Xuesaitong may relieve HHPH induced by COPD through inhibiting the activation of P38MAPK and ERK1/2 pathway.